Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225706 · ClinicalTrials.gov registry record · Phase 3
A Study of Caldolor in Hospitalized Febrile Pediatric Patients
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00225706 is a Phase 3 study that has completed, run by Cumberland Pharmaceuticals.
The verdict
NCT00225706, a Phase 3 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The primary objective of this study of Caldolor administered to febrile hospitalized pediatric patients every 6 hours for 24 hours is to determine the clinical equivalence of a single dose of Caldolor compared to acetaminophen (paracetamol; APAP) for the treatment of fever as measured by the AUC Tº within the first 6 hours of treatment (as compared to a target temperature of 98.6ºF \[37.0ºC\]).
Interventions
- DRUG Caldolor
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225706
The ClinicalTrials.gov registry entry for NCT00225706 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Caldolor is the first listed.
NCT00225706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225706 about?
NCT00225706 is a clinical study titled "A Study of Caldolor in Hospitalized Febrile Pediatric Patients". The primary objective of this study of Caldolor administered to febrile hospitalized pediatric patients every 6 hours for 24 hours is to determine the clinical equivalence of a single dose of Caldolor compared to acetaminophen (paracetamol; APAP) for the treatment of fever as measured by the AUC Tº ...
What is the current status of trial NCT00225706?
This trial is currently completed. It is a Phase 3 study. The study started on 2005-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00225706?
The interventions under investigation include: Caldolor (DRUG).
Who is sponsoring clinical trial NCT00225706?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.